Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Nasopharyngeal Carcinoma 11Leukemia, Myeloid, Acute 4Carcinoma, Non-Small-Cell Lung 4Nasopharyngeal Neoplasms 3Lung Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Myelodysplastic Syndromes 2Turcot syndrome 1Tongue Neoplasms 1Thrombocythemia, Essential 1Stomach Neoplasms 1Rhabdoid Tumor 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Patient Outcome Assessment 1Pathologic Complete Response 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Myeloproliferative Disorders 1Multiple Myeloma 1Medulloblastoma 1Lymphoma 1Locally Advanced Malignant Neoplasm 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Hypopharyngeal Neoplasms 1

Interventions

trifluridine tipiracil drug combination 1camrelizumab 1anlotinib 1Radiotherapy 1Induction Chemotherapy 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
ESCC × Induction Chemotherapy × Clear all
NCT07015489 2025-06-11

Concurrent Radiotherapy Following Induction Chemoimmunotherapy for Locally Advanced Esophageal Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Completed
44 enrolled

ESCC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡